Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. News
  7. Summary
    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eisai : AbbVie, Eisai, and EA Pharma Launch 'Humira Support Tool Ordering Service for Patients' - an Initiative to Improve Patients' Adherence to Humira Therapy

09/14/2021 | 10:39am EDT

AbbVie GK (Headquarters: Tokyo, President: James Feliciano, 'AbbVie'), Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai'), and EA Pharma Co., Ltd. (Headquarters: Tokyo, CEO: Yuji Matsue, 'EA Pharma') announced today that, on September 13, 2021, the companies launched 'Humira Support Tool Ordering Service for Patients' an initiative intended to improve patients' adherence to Humira therapy.

'Humira Support Tool Ordering Service for Patients' is a free-of-charge service that assists patients on Humira therapy by directly delivering support tools to their home or other requested location. Patients can use this service by applying on the website or using a designated form to request support tools such as containers for disposal of used syringes, bags for disposal of used pens, disease-specific health management notebooks, and disease-specific medication guides for patients. The requested support tools are delivered to their home or other desired location free-of-charge.

Formerly, patients received the support tools they needed during a clinic visit. When the support tools they needed were not available at the clinic, it took time to deliver the support tools to patients, potentially resulting in unavailability of the tools when needed. In addition, some large-sized tools, such as containers for disposal of used syringes, put a burden on patients who had to carry them home. This service is intended to allow patients to shorten the time required to receive support tools and reduce the burden of carrying them.

In Japan, AbbVie is the marketing and manufacturing authorization holder for Humira. Abbvie and Eisai are co-promoting Humira for the indications in the fields of rheumatoid arthritis, plaque psoriasis, arthropathic psoriasis, ankylosing spondylitis, juvenile idiopathic arthritis, uveitis, pustular psoriasis, hidradenitis suppurativa and pyoderma gangrenosum. For the indications in the field of gastrointestinal disease (i.e., Crohn's disease, intestinal Bechet's disease and ulcerative colitis), AbbVie is co-promoting Humira with EA Pharma, commissioned by Eisai for promotion.

Through providing 'Humira Support Tool Ordering Service for Patients,' AbbVie, Eisai, and EA Pharma are committed to further enhancing patient support programs and contributing to improved treatment adherence.

About HUMIRA

HUMIRA is a fully human anti-TNF-? monoclonal antibody. In Japan, it is approved for 'the treatment of rheumatoid arthritis (including inhibition of the progression of structural damage); hidradenitis suppurativa, pyoderma gangrenosum, the treatment of plaque psoriasis, arthritic psoriasis, pustular psoriasis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis*, intestinal Behcet's disease, and non-infectious intermediate, posterior and panuveitis that are refractory to the conventional therapies, induction and maintenance therapy for moderate to severely active Crohn's disease (limited to patients who have had an inadequate response to conventional therapy), and treatment of moderate to severe ulcerative colitis (limited to patients who have had an inadequate response to conventional therapy).'

HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL is approved. HUMIRA for Subcutaneous Injection 80 mg Syringe 0.8 mL and HUMIRA for Subcutaneous Injection 80 mg Pen 0.8 mL are yet to be approved.

Nonproprietary name: Adalimumab

Brand name: Fully Human Anti- TNF- Monoclonal Antibody 'HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL; HUMIRA for Subcutaneous Injection 40 mg Syringe 0.4 mL; HUMIRA for Subcutaneous Injection 80 mg Syringe 0.8 mL; HUMIRA for Subcutaneous Injection 40 mg Pen 0.4 mL; and HUMIRA for Subcutaneous Injection 80 mg Pen 0.8 mL'

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com.

Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as 'giving first thought to patients and their families and to increasing the benefits health care provides,' which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. For more information about Eisai Co., Ltd., please visit www.eisai.com.

About EA Pharma

EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd. for gastrointestinal disease area, was established in April 2016 by integration of the gastrointestinal business unit with more than 60 year's history of the Eisai Group and the gastrointestinal business unit of the Ajinomoto Group having amino acid as its business core. EA Pharma Co., Ltd., is a gastrointestinal specialty pharmaceutical company with a full value chain covering R&D, production & logistics and sales & marketing.

For further information on EA Pharma Co., Ltd., please visit https://www.eapharma.co.jp/en.

Contact:

AbbVie GK

Public Affairs

TEL: +81-(0)3-4577-1112

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about EISAI CO., LTD.
10/17EISAI : and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Positive EU CHMP Opinions ..
AQ
10/17EISAI : and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Positive EU CHMP Opinions ..
PU
10/15Merck, Eisai Get CHMP Backing for Lenvima-Keytruda Combo in Two Cancers
DJ
09/29EISAI CO., LTD. : Ex-dividend day for interim dividend
FA
09/28EISAI : Starts Rolling Submission To Seek US Approval For Alzheimer's Disease Therapy
MT
09/27EISAI : INITIATES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF ..
PU
09/27BIOARCTIC : Eisai initiates rolling submission for the US FDA Biologics license applicatio..
AQ
09/27BioArctic AB's partner Eisai Initiates Rolling Submission for the US FDA Biologics Lice..
CI
09/27Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Application Of..
CI
09/27EISAI : Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval
AQ
More news
Analyst Recommendations on EISAI CO., LTD.
More recommendations
Financials
Sales 2022 695 B 6 072 M 6 072 M
Net income 2022 56 365 M 493 M 493 M
Net cash 2022 155 B 1 356 M 1 356 M
P/E ratio 2022 41,4x
Yield 2022 1,98%
Capitalization 2 333 B 20 437 M 20 395 M
EV / Sales 2022 3,14x
EV / Sales 2023 2,97x
Nbr of Employees 11 237
Free-Float 87,9%
Chart EISAI CO., LTD.
Duration : Period :
Eisai Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EISAI CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 8 139,00 JPY
Average target price 11 773,85 JPY
Spread / Average Target 44,7%
EPS Revisions
Managers and Directors
Haruo Naito Chief Executive Officer & Representative Director
Ryohei Yanagi Chief Financial Officer
Yasuhiko Katoh Chairman
Edward Stewart Geary Chief Medical Officer & Managing Executive Officer
Lynn D. Kramer Chief Medical & Chief Clinical Officer-Neurology
Sector and Competitors
1st jan.Capi. (M$)
EISAI CO., LTD.10.40%20 437
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.12.71%232 621
ELI LILLY AND COMPANY40.89%215 657